Potential Glaxo loss could be Lilly’s gain
Eli Lilly and Co. could face the juicy prospect of a $2 billion hole in the diabetes market if the Food and Drug Administration acts on a recommendation from one of its safety scientists. David Graham is set to tell FDA advisers today to pull diabetes pill Avandia from the U.S. market, according to Bloomberg. […]